To conduct performance evaluations, including operational characteristics of malaria rapid diagnostic tests submitted for WHO for assessment under the WHO Prequalification of In Vitro Diagnostics submitted to WHO for assessment under the Emergency Use Listing.

To pilot the training of scientists at the first PARMA (PMI-supported Antimalarial Resistance Monitoring in Africa) site in Africa in Senegal.

To collect, manage and analyze data on the safety and efficacy of tafenoquine (Krintafel) used for anti-relapse therapy of malaria in the United States.